Type 1 diabetes (T1D) affects roughly 9.5 million people globally, and for most of the disease’s history, clinical development has focused on improving insulin delivery, glucose monitoring, and glycemic control. That paradigm is shifting rapidly. Scientific advances have moved the field beyond disease management toward disease-modifying therapies, beta-cell replacement strategies, immune interventions, and cure-directed approaches. This is collectively reshaping endpoints, target populations, safety considerations, and regulatory expectations along the way. For biotech and emerging biopharma companies, the greatest challenges are no longer scientific feasibility but operational execution and moving from an early-stage program to regulatory approval demands expert-level understanding of the science, the evolving clinical landscape, and the operational factors that determine success.
Read the full article to learn about:
- How the T1D treatment paradigm is shifting, with the first disease-modifying therapy (teplizumab) and first allogeneic islet cell therapy (Lantidra) redefining what’s possible beyond insulin management
- The evolving therapeutic pipeline, including immune-modulating therapies, antigen-specific approaches, and cell-based therapies aimed at preserving or restoring beta-cell function
- How emerging therapies are reshaping clinical trial design, with endpoints shifting from traditional glycemic measures toward beta-cell preservation, C-peptide outcomes, and CGM- and MMTT-based metrics
- Operational and regulatory considerations that vary by therapeutic modality, and why aligning modality, geography, manufacturing strategy, and long-term development objectives from the outset is critical to building a scalable pathway to registration
Authors:
